Elotuzumab in Previously Treated Multiple Myeloma

On November 30, 2015, elotuzu­mab (Empliciti) was approved for use in combination with lenalidomide (Revlimid) and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. 

 The ASCO Post

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.